BridgeBio Pharma Inc (BBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $15.25B
Last updated: Nov 17, 2026 at 11:05 AM ET
BridgeBio Pharma Inc (BBIO) Stock Forecast
Analysts expect BridgeBio Pharma (BBIO) to earn -$2.49 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.10B. Of 22 analysts, 19 rate the stock Buy or Strong Buy, 3 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 4 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 22 ratings average 1.91, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 86% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 5 | 22.7% |
| Buy | 14 | 63.6% |
| Hold | 3 | 13.6% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 22
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 50.9%.
- Fiscal year ending Dec 31, 2026
- -$2.49
- EPS consensus, revenue $1.10B
- Fiscal year ending Dec 31, 2027
- -$0.27
- EPS consensus, revenue $1.66B
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.49 | -$2.81 to -$2.09 | 7 | $1.10B | $1.07B to $1.12B | 16 |
| Dec 31, 2027 | -$0.27 | -$1.91 to $1.31 | 7 | $1.66B | $1.48B to $1.88B | 18 |
Quarterly Estimates
The EPS consensus rises from -$0.62 for the quarter ending Dec 31, 2026 to -$0.37 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.62 | -$0.85 to -$0.17 | 22 | $306.94M | $267.83M to $334.57M | 20 |
| Mar 31, 2027 | -$0.37 | -$0.62 to -$0.15 | 4 | $338.05M | $323.00M to $350.80M | 9 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 5 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 4 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$2.19.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.49 | -$2.62 | -$2.58 | -$2.58 | -$2.19 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.27 | -$0.22 | $0.03 | $0.03 | $0.58 | N/A |
| Quarter ending Mar 31, 2027 | -$0.37 | -$0.34 | -$0.36 | -$0.36 | -$0.11 | N/A |
Frequently Asked Questions About BBIO
What is the BBIO stock forecast?
Consensus analyst estimates put BridgeBio Pharma's EPS at -$2.49 for the fiscal year ending Dec 31, 2026, on revenue of $1.10B. The consensus rating from 22 analysts is Buy.
How do analysts rate BBIO stock?
Of 22 analysts covering BridgeBio Pharma, 5 rate it Strong Buy, 14 Buy, 3 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from BBIO next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.49, with estimates from -$2.81 to -$2.09 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.27, with estimates from -$1.91 to $1.31 from 7 analysts.
What revenue do analysts expect from BridgeBio Pharma next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.10B, with estimates from $1.07B to $1.12B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.66B, with estimates from $1.48B to $1.88B.
How many analysts cover BBIO?
22 analysts rate BridgeBio Pharma stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
BBIO pages: Overview, Earnings, Forecast, Financials, Competitors